Canada Pharmaceutical Market Size, Share & Trends Analysis Report By Drug Type, By Product (Branded), By Type (Prescription, OTC), By Disease (Cancer), By Route Of Administration, By Formulation, By Age Group, By End-use, And Segment Forecasts, 2025 - 203
Description
Canada Pharmaceutical Market Growth & Trends
The Canada pharmaceutical market is anticipated to reach USD 76.9 billion by 2030 and expand at a CAGR of 7.0% from 2025 to 2030, according to a new report by Grand View Research, Inc. Several driving factors influence this significant and highly regulated industry. One of the primary drivers is Canada's aging population. With a growing number of seniors, there's a heightened demand for pharmaceuticals and healthcare services. For example, medications for conditions like osteoarthritis and Alzheimer's are in high demand due to the aging demographic.
Government regulation also plays a crucial role in shaping the pharmaceutical market. Health Canada, the country's regulatory body, oversees drug safety and efficacy. For instance, the approval and regulation of prescription drugs like insulin and antibiotics ensure the quality and safety of medicines available in the market. Research and development (R&D) efforts are another crucial factor. Canada boasts a strong R&D sector, with pharmaceutical companies like Apotex and Valeo Pharma conducting innovative research. For example, developing biologic drugs for conditions like cancer and autoimmune diseases benefits patients and contributes to economic growth.
Moreover, product launches by key players in the market will further propel the Canadian pharmaceutical market growth in the forecast period. For instance, the approval of Arexvy, a respiratory syncytial virus (RSV) vaccine, for individuals aged 60 and older is a significant development in Canada's healthcare landscape. RSV is a common cause of lower respiratory tract disease (LRTD) in older adults, making this vaccine a valuable addition to the preventive measures available. This approval expands the vaccine portfolio of GSK in Canada and addresses a specific healthcare need for the aging population. Introducing Arexvy is especially noteworthy as it marks the first approval of the RSV vaccine for older adults in the country. RSV can lead to severe respiratory illnesses, and older adults are a particularly vulnerable demographic.
Canada Pharmaceutical Market Report Highlights
The Canada pharmaceutical market is anticipated to reach USD 76.9 billion by 2030 and expand at a CAGR of 7.0% from 2025 to 2030, according to a new report by Grand View Research, Inc. Several driving factors influence this significant and highly regulated industry. One of the primary drivers is Canada's aging population. With a growing number of seniors, there's a heightened demand for pharmaceuticals and healthcare services. For example, medications for conditions like osteoarthritis and Alzheimer's are in high demand due to the aging demographic.
Government regulation also plays a crucial role in shaping the pharmaceutical market. Health Canada, the country's regulatory body, oversees drug safety and efficacy. For instance, the approval and regulation of prescription drugs like insulin and antibiotics ensure the quality and safety of medicines available in the market. Research and development (R&D) efforts are another crucial factor. Canada boasts a strong R&D sector, with pharmaceutical companies like Apotex and Valeo Pharma conducting innovative research. For example, developing biologic drugs for conditions like cancer and autoimmune diseases benefits patients and contributes to economic growth.
Moreover, product launches by key players in the market will further propel the Canadian pharmaceutical market growth in the forecast period. For instance, the approval of Arexvy, a respiratory syncytial virus (RSV) vaccine, for individuals aged 60 and older is a significant development in Canada's healthcare landscape. RSV is a common cause of lower respiratory tract disease (LRTD) in older adults, making this vaccine a valuable addition to the preventive measures available. This approval expands the vaccine portfolio of GSK in Canada and addresses a specific healthcare need for the aging population. Introducing Arexvy is especially noteworthy as it marks the first approval of the RSV vaccine for older adults in the country. RSV can lead to severe respiratory illnesses, and older adults are a particularly vulnerable demographic.
Canada Pharmaceutical Market Report Highlights
- By disease, the cancer segment led the market with the largest revenue share of 18.1% in 2024, attributed to the increasing prevalence of cancer and the ongoing development of advanced treatments.
- The parenteral segment is set to experience the fastest growth during the forecast period, fueled by the increasing demand for injectable medications.
- By formulation, the tablets segment accounted for the largest market share in 2024 due to their convenience, affordability, and ease of administration.
- The sprays segment is anticipated to grow at the fastest CAGR from 2025 to 2030, propelled by their user-friendly nature and precise dosing capabilities.
- By end use, the hospitals segment held the largest market share in 2024, propelled by the increasing number of hospitals, leading to higher demand for pharmaceutical drugs to treat various medical conditions.
Table of Contents
119 Pages
- Chapter 1. Methodology and Scope
- 1.1. Market Segmentation & Scope
- 1.2. Segment Definitions
- 1.2.1. Drug Type
- 1.2.2. Product
- 1.2.3. Type
- 1.2.4. Disease
- 1.2.5. Route of Administration
- 1.2.6. Formulation
- 1.2.7. Age Group
- 1.2.8. End Use
- 1.2.9. Estimates and Forecast Timeline
- 1.3. Research Methodology
- 1.4. Information Procurement
- 1.4.1. Purchased Database
- 1.4.2. GVR’s Internal Database
- 1.4.3. Secondary Sources
- 1.4.4. Primary Research
- 1.4.5. Details of Primary Research
- 1.5. Information or Data Analysis
- 1.5.1. Data Analysis Models
- 1.6. Market Formulation & Validation
- 1.7. Model Details
- 1.8. List of Secondary Sources
- 1.9. List of Primary Sources
- 1.10. Objectives
- Chapter 2. Executive Summary
- 2.1. Market Outlook
- 2.2. Segment Outlook
- 2.2.1. Drug Type Outlook
- 2.2.2. Product Outlook
- 2.2.3. Type Outlook
- 2.2.4. Disease Outlook
- 2.2.5. Route of Administration Outlook
- 2.2.6. Formulation Outlook
- 2.2.7. Age Group Outlook
- 2.2.8. End Use Outlook
- 2.3. Competitive Scenario
- Chapter 3. Canada Pharmaceutical Market Variables, Trends, & Scope
- 3.1. Market Lineage Outlook
- 3.1.1. Parent Market Outlook
- 3.1.2. Related/Ancillary Market Outlook
- 3.2. Market Dynamics
- 3.2.1. Market Driver Analysis
- 3.2.2. Market Restraint Analysis
- 3.3. Canada Pharmaceutical Market Analysis Tools
- 3.3.1. Industry Analysis - Porter’s Five Forces Analysis
- 3.3.1.1. Supplier Power
- 3.3.1.2. Buyer Power
- 3.3.1.3. Substitution Threat
- 3.3.1.4. Threat of New Entrant
- 3.3.1.5. Competitive Rivalry
- 3.3.2. PESTLE Analysis
- 3.3.2.1. Political Landscape
- 3.3.2.2. Technological Landscape
- 3.3.2.3. Economic Landscape
- Chapter 4. Canada Pharmaceutical Market: Drug Type Business Analysis
- 4.1. Drug Type Segment Dashboard
- 4.2. Canada Pharmaceutical Market: Drug Type Movement Analysis
- 4.3. Canada Pharmaceutical Market Size & Trend Analysis, By Drug Type, 2018 to 2030 (USD Billion)
- 4.4. Biologics & Biosimilars (Large Molecules)
- 4.4.1. Market Estimates and Forecasts 2018 to 2030 (USD Billion)
- 4.4.2. Monoclonal Antibodies
- 4.4.2.1. Market Estimates and Forecasts 2018 to 2030 (USD Billion)
- 4.4.3. Vaccines
- 4.4.3.1. Market Estimates and Forecasts 2018 to 2030 (USD Billion)
- 4.4.4. Cell & Gene Therapy
- 4.4.4.1. Market Estimates and Forecasts 2018 to 2030 (USD Billion)
- 4.4.5. Others
- 4.4.5.1. Market Estimates and Forecasts 2018 to 2030 (USD Billion)
- 4.5. Conventional Drugs (Small Molecules)
- 4.5.1. Market Estimates and Forecasts 2018 to 2030 (USD Billion)
- Chapter 5. Canada Pharmaceutical Market: Product Business Analysis
- 5.1. Product Segment Dashboard
- 5.2. Canada Pharmaceutical Market: Product Movement Analysis
- 5.3. Canada Pharmaceutical Market Size & Trend Analysis, By Product, 2018 to 2030 (USD Billion)
- 5.4. Branded
- 5.4.1. Market Estimates and Forecasts 2018 to 2030 (USD Billion)
- 5.5. Generics
- 5.5.1. Market Estimates and Forecasts 2018 to 2030 (USD Billion)
- Chapter 6. Canada Pharmaceutical Market: Type Business Analysis
- 6.1. Type Segment Dashboard
- 6.2. Canada Pharmaceutical Market: Type Movement Analysis
- 6.3. Canada Pharmaceutical Market Size & Trend Analysis, By Type, 2018 to 2030 (USD Billion)
- 6.4. Prescription
- 6.4.1. Market Estimates and Forecasts 2018 to 2030 (USD Billion)
- 6.5. OTC
- 6.5.1. Market Estimates and Forecasts 2018 to 2030 (USD Billion)
- Chapter 7. Canada Pharmaceutical Market: Disease Business Analysis
- 7.1. Disease Segment Dashboard
- 7.2. Canada Pharmaceutical Market: Disease Movement Analysis
- 7.3. Canada Pharmaceutical Market Size & Trend Analysis, By Disease, 2018 to 2030 (USD Billion)
- 7.4. Cardiovascular diseases
- 7.4.1. Market Estimates and Forecasts 2018 to 2030 (USD Billion)
- 7.5. Cancer
- 7.5.1. Market Estimates and Forecasts 2018 to 2030 (USD Billion)
- 7.6. Diabetes
- 7.6.1. Market Estimates and Forecasts 2018 to 2030 (USD Billion)
- 7.7. Infectious diseases
- 7.7.1. Market Estimates and Forecasts 2018 to 2030 (USD Billion)
- 7.8. Neurological Disorders
- 7.8.1. Market Estimates and Forecasts 2018 to 2030 (USD Billion)
- 7.9. Respiratory diseases
- 7.9.1. Market Estimates and Forecasts 2018 to 2030 (USD Billion)
- 7.10. Autoimmune diseases
- 7.10.1. Market Estimates and Forecasts 2018 to 2030 (USD Billion)
- 7.11. Mental health disorders
- 7.11.1. Market Estimates and Forecasts 2018 to 2030 (USD Billion)
- 7.12. Gastrointestinal disorders
- 7.12.1. Market Estimates and Forecasts 2018 to 2030 (USD Billion)
- 7.13. Women’s Health Diseases
- 7.13.1. Market Estimates and Forecasts 2018 to 2030 (USD Billion)
- 7.14. Genetic and Rare genetic diseases
- 7.14.1. Market Estimates and Forecasts 2018 to 2030 (USD Billion)
- 7.15. Dermatological conditions
- 7.15.1. Market Estimates and Forecasts 2018 to 2030 (USD Billion)
- 7.16. Obesity
- 7.16.1. Market Estimates and Forecasts 2018 to 2030 (USD Billion)
- 7.17. Renal diseases
- 7.17.1. Market Estimates and Forecasts 2018 to 2030 (USD Billion)
- 7.18. Liver conditions
- 7.18.1. Market Estimates and Forecasts 2018 to 2030 (USD Billion)
- 7.19. Hematological disorders
- 7.19.1. Market Estimates and Forecasts 2018 to 2030 (USD Billion)
- 7.20. Eye conditions
- 7.20.1. Market Estimates and Forecasts 2018 to 2030 (USD Billion)
- 7.21. Infertility conditions
- 7.21.1. Market Estimates and Forecasts 2018 to 2030 (USD Billion)
- 7.22. Endocrine disorders
- 7.22.1. Market Estimates and Forecasts 2018 to 2030 (USD Billion)
- 7.23. Allergies
- 7.23.1. Market Estimates and Forecasts 2018 to 2030 (USD Billion)
- 7.24. Others
- 7.24.1. Market Estimates and Forecasts 2018 to 2030 (USD Billion)
- Chapter 8. Canada Pharmaceutical Market: Route of Administration Business Analysis
- 8.1. Route of Administration Segment Dashboard
- 8.2. Canada Pharmaceutical Market: Route of Administration Movement Analysis
- 8.3. Canada Pharmaceutical Market Size & Trend Analysis, By Route of Administration, 2018 to 2030 (USD Billion)
- 8.4. Oral
- 8.4.1. Market Estimates and Forecasts 2018 to 2030 (USD Billion)
- 8.5. Topical
- 8.5.1. Market Estimates and Forecasts 2018 to 2030 (USD Billion)
- 8.6. Parenteral
- 8.6.1. Market Estimates and Forecasts 2018 to 2030 (USD Billion)
- 8.6.2. Intravenous
- 8.6.2.1. Market Estimates and Forecasts 2018 to 2030 (USD Billion)
- 8.6.3. Intramuscular
- 8.6.3.1. Market Estimates and Forecasts 2018 to 2030 (USD Billion)
- 8.7. Inhalations
- 8.7.1. Market Estimates and Forecasts 2018 to 2030 (USD Billion)
- 8.8. Other Routes of Administration
- 8.8.1. Market Estimates and Forecasts 2018 to 2030 (USD Billion)
- Chapter 9. Canada Pharmaceutical Market: Formulation Business Analysis
- 9.1. Formulation Segment Dashboard
- 9.2. Canada Pharmaceutical Market: Formulation Movement Analysis
- 9.3. Canada Pharmaceutical Market Size & Trend Analysis, By Formulation, 2018 to 2030 (USD Billion)
- 9.4. Tablets
- 9.4.1. Market Estimates and Forecasts 2018 to 2030 (USD Billion)
- 9.5. Capsules
- 9.5.1. Market Estimates and Forecasts 2018 to 2030 (USD Billion)
- 9.6. Injectable
- 9.6.1. Market Estimates and Forecasts 2018 to 2030 (USD Billion)
- 9.7. Sprays
- 9.7.1. Market Estimates and Forecasts 2018 to 2030 (USD Billion)
- 9.8. Suspensions
- 9.8.1. Market Estimates and Forecasts 2018 to 2030 (USD Billion)
- 9.9. Powders
- 9.9.1. Market Estimates and Forecasts 2018 to 2030 (USD Billion)
- 9.10. Other Formulations
- 9.10.1. Market Estimates and Forecasts 2018 to 2030 (USD Billion)
- Chapter 10. Canada Pharmaceutical Market: Age Group Business Analysis
- 10.1. Age Group Segment Dashboard
- 10.2. Canada Pharmaceutical Market: Age Group Movement Analysis
- 10.3. Canada Pharmaceutical Market Size & Trend Analysis, By Age Group, 2018 to 2030 (USD Billion)
- 10.4. Children & Adolescents
- 10.4.1. Market Estimates and Forecasts 2018 to 2030 (USD Billion)
- 10.5. Adults
- 10.5.1. Market Estimates and Forecasts 2018 to 2030 (USD Billion)
- 10.6. Geriatric
- 10.6.1. Market Estimates and Forecasts 2018 to 2030 (USD Billion)
- Chapter 11. Canada Pharmaceutical Market: End Use Business Analysis
- 11.1. End Use Segment Dashboard
- 11.2. Canada Pharmaceutical Market: End Use Movement Analysis
- 11.3. Canada Pharmaceutical Market Size & Trend Analysis, By End Use, 2018 to 2030 (USD Billion)
- 11.4. Hospitals
- 11.4.1. Market Estimates and Forecasts 2018 to 2030 (USD Billion)
- 11.5. Clinics
- 11.5.1. Market Estimates and Forecasts 2018 to 2030 (USD Billion)
- 11.6. Others
- 11.6.1. Market Estimates and Forecasts 2018 to 2030 (USD Billion)
- Chapter 12. Competitive Landscape
- 12.1. Recent Developments & Impact Analysis, By Key Market Participants
- 12.2. Company/ Competition Categorization
- 12.3. Vendor Landscape
- 12.3.1. Key Company Heat Map Analysis, 2024
- 12.4. Company Profiles
- 12.4.1. F. Hoffmann-La Roche Ltd
- 12.4.1.1. Company Overview
- 12.4.1.2. Financial Performance
- 12.4.1.3. Product Benchmarking
- 12.4.1.4. Strategic Initiatives
- 12.4.2. Novartis AG
- 12.4.2.1. Company Overview
- 12.4.2.2. Financial Performance
- 12.4.2.3. Product Benchmarking
- 12.4.2.4. Strategic Initiatives
- 12.4.3. GSK plc
- 12.4.3.1. Company Overview
- 12.4.3.2. Financial Performance
- 12.4.3.3. Product Benchmarking
- 12.4.3.4. Strategic Initiatives
- 12.4.4. Pfizer Inc.
- 12.4.4.1. Company Overview
- 12.4.4.2. Financial Performance
- 12.4.4.3. Product Benchmarking
- 12.4.4.4. Strategic Initiatives
- 12.4.5. Merck & Co., Inc.
- 12.4.5.1. Company Overview
- 12.4.5.2. Financial Performance
- 12.4.5.3. Product Benchmarking
- 12.4.5.4. Strategic Initiatives
- 12.4.6. AstraZeneca
- 12.4.6.1. Company Overview
- 12.4.6.2. Financial Performance
- 12.4.6.3. Product Benchmarking
- 12.4.6.4. Strategic Initiatives
- 12.4.7. Johnson & Johnson Services, Inc.
- 12.4.7.1. Company Overview
- 12.4.7.2. Financial Performance
- 12.4.7.3. Product Benchmarking
- 12.4.7.4. Strategic Initiatives
- 12.4.8. Sanofi
- 12.4.8.1. Company Overview
- 12.4.8.2. Financial Performance
- 12.4.8.3. Product Benchmarking
- 12.4.8.4. Strategic Initiatives
- 12.4.9. Eli Lilly and Company
- 12.4.9.1. Company Overview
- 12.4.9.2. Financial Performance
- 12.4.9.3. Product Benchmarking
- 12.4.9.4. Strategic Initiatives
- 12.4.10. AbbVie Inc.
- 12.4.10.1. Company Overview
- 12.4.10.2. Financial Performance
- 12.4.10.3. Product Benchmarking
- 12.4.10.4. Strategic Initiatives
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
